Sweden · Delayed Price · Currency is SEK Careium AB (Publ) Earnings Call Transcripts
Fiscal Year 2025
-
Q2 2025 saw an 11.9% sales decline, but gross margin improved and key contracts were won in France and the UK. Guidance for a stronger H2 is maintained, with optimism for improved sales and profitability as major contracts ramp up.
-
Q1 saw growth in all markets except Sweden, with strong margin performance aided by a UK one-time effect. Guidance for 2025 is maintained, focusing on B2C, assisted living, and acquisitions, despite ongoing Swedish market headwinds.
Fiscal Year 2024
-
Carium delivered strong Q4 and full-year profitability, with robust growth in the UK and other European markets, despite Swedish market delays. 2025 guidance anticipates higher sales and profitability, with a focus on new markets and acquisitions.
-
Europe’s aging population is driving rapid growth in technology-enabled care, with the company focusing on organic expansion in major markets, product innovation, and selective acquisitions. Recurring revenue and a broad, quality-focused portfolio underpin its competitive edge.
-
Q3 2024 saw sales decline due to infrastructure delays, but profitability remained strong and new innovations like the Eye Care Center and Spanish market entry support future growth. Full-year guidance is maintained, with normalization expected as transitions resolve.
-
Q2 2024 saw stable growth and improved profitability despite market slowdowns in the UK and Sweden, with strong gains in other European markets and the launch of the Resilient SIM. Full-year guidance is maintained, and further R&D investment is prioritized.